Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014,64:9–29.
Article
PubMed
Google Scholar
Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 2006,95 Suppl 1:S161–S192.
Article
PubMed
Google Scholar
Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer, 2011,11:719–725.
Article
PubMed Central
CAS
PubMed
Google Scholar
Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol, 2006,60:159–179.
Article
PubMed
Google Scholar
Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002,7 Suppl 5:20–28.
Article
CAS
PubMed
Google Scholar
Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer, 2011,21:750–755.
Article
Google Scholar
Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer, 2011,21:771–775.
Article
PubMed
Google Scholar
Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol, 2012,23 Suppl 10:x128–x131.
Article
PubMed
Google Scholar
Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep, 2011,13:459–471.
Article
CAS
PubMed
Google Scholar
Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol, 2007,64:129–138.
Article
PubMed
Google Scholar
Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial. Lancet, 2003,361:2099–2106.
Article
CAS
PubMed
Google Scholar
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol, 2010,28:3323–3329.
Article
CAS
PubMed
Google Scholar
Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer, 2009,19 Suppl 2:S63–S67.
Article
PubMed
Google Scholar
Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer, 2009,9:415–428.
Article
PubMed Central
CAS
PubMed
Google Scholar
Romero I, Sun CC, Wong KK, et al. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol, 2013, 130:660–666.
Article
PubMed
Google Scholar
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011,474:609–615.
Article
Google Scholar
Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 2011,306:1557–1565.
Article
PubMed Central
CAS
PubMed
Google Scholar
Majdak EJ, Debniak J, Milczek T, et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer, 2005,104:1004–1012.
Article
PubMed
Google Scholar
Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 2012,307:382–390.
Article
PubMed Central
CAS
PubMed
Google Scholar
Varga D, Deniz M, Schwentner L, et al. Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci, 2013,14:640–673.
Article
PubMed Central
CAS
PubMed
Google Scholar
Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer, 2008,44:609–618.
Article
CAS
PubMed
Google Scholar
Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep, 2009,26:322–337.
Article
CAS
PubMed
Google Scholar
Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry, 1996,35:13303–13309.
Article
CAS
PubMed
Google Scholar
Erba E, Cavallaro E, Damia G, et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res, 2004,14:579–587.
CAS
PubMed
Google Scholar
Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem, 1999,42:2493–2497.
Article
CAS
PubMed
Google Scholar
D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther, 2010,9:2157–2163.
Article
PubMed
Google Scholar
Pardo B, Salazar R, Ciruelos E, et al. Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function. Med Oncol, 2012,29:2240–2250.
Article
CAS
PubMed
Google Scholar
Vidal L, Magem M, Barlow C, et al. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs, 2012,30:616–628.
Article
CAS
PubMed
Google Scholar
del Campo JM, Sessa C, Krasner CN, et al. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol, 2013,30:435.
Article
PubMed
Google Scholar
Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol, 2005,23:1867–1874.
Article
CAS
PubMed
Google Scholar
Krasner CN, McMeekin DS, Chan S, et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer, 2007,97:1618–1624.
Article
PubMed Central
CAS
PubMed
Google Scholar
Del Campo JM, Roszak A, Bidzinski M, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol, 2009,20:1794–1802.
Article
PubMed
Google Scholar
Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol, 2010,28:3107–3114.
Article
CAS
PubMed
Google Scholar
Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer, 2012,48:2361–2368.
Article
CAS
PubMed
Google Scholar
Poveda A, Ray-Coquard I, Romero I, et al. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin. Cancer Treat Rev, 2014,40:366–375.
Article
CAS
PubMed
Google Scholar
Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol, 2011,22:39–48.
Article
PubMed Central
CAS
PubMed
Google Scholar
Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res, 2003,63:5902–5908.
CAS
PubMed
Google Scholar
Lebedinsky C, Gomez J, Park YC, et al. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis. Cancer Chemother Pharmacol, 2011,68:1223–1231.
Article
CAS
PubMed
Google Scholar
Le Cesne A, Yovine A, Blay JY, et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs, 2012,30:1193–1202.
Article
CAS
PubMed
Google Scholar
Lorusso D, Ferrandina G, Pignata S, et al. Trabectedin in patients with BRCA mutated and BRCAness phenotype advanced ovarian cancer (AOC): phase II prospective MITO-15 study. Ann Oncol, 2014,25:iv309.
Google Scholar
Poveda A, Berton-Rigaud D, Laure Ray-Coquard I, et al. Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: results of a two-stage, controlled phase II study. J Clin Oncol, 2014,32:abstr 5505.
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 2007,7:573–584.
Article
CAS
PubMed
Google Scholar
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature, 2001,411:366–374.
Article
CAS
PubMed
Google Scholar
Takebayashi Y, Nakayama K, Kanzaki A, et al. Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett, 2001,174:115–125.
Article
CAS
PubMed
Google Scholar
Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer, 2012,12:104–120.
PubMed Central
CAS
PubMed
Google Scholar
Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer, 2001,92:583–588.
Article
CAS
PubMed
Google Scholar
Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer, 2001,37:97–105.
Article
CAS
PubMed
Google Scholar
Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med, 2001,7:961–966.
Article
CAS
PubMed
Google Scholar
Soares DG, Poletto NP, Bonatto D, et al. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol, 2005,70:59–69.
Article
CAS
PubMed
Google Scholar
Damia G, Imperatori L, Stefanini M, et al. Sensitivity of cho mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer, 1996,66:779–783.
Article
CAS
PubMed
Google Scholar
Herrero AB, Martin-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res, 2006,66:8155–8162.
Article
CAS
PubMed
Google Scholar
Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A, 2007,104:13062–13067.
Article
PubMed Central
PubMed
Google Scholar
Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther, 2008,7:10–18.
Article
CAS
PubMed
Google Scholar
Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res, 2002,62:4899–4902.
CAS
PubMed
Google Scholar
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer, 2004,4:814–819.
Article
CAS
PubMed
Google Scholar
Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res, 2006,12:4463–4468.
Article
CAS
PubMed
Google Scholar
Monk BJ, Kaye SB, Poveda A, et al. Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecol Oncol, 2014,132:176–180.
Article
CAS
PubMed
Google Scholar
Stracker TH, Petrini JH. The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol, 2011,12:90–103.
Article
PubMed Central
CAS
PubMed
Google Scholar
D’Incalci M, Badri N, Galmarini CM, et al. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer, 2014,111:646–650.
Article
PubMed Central
PubMed
Google Scholar
Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell, 2013,23:249–262.
Article
CAS
PubMed
Google Scholar
Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res, 2005,65:2964–2971.
Article
CAS
PubMed
Google Scholar
Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene, 2014,33:5201–5210.
Article
PubMed
Google Scholar
Feuerhahn S, Giraudon C, Martinez-Diez M, et al. XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids. Chem Biol, 2011,18:988–999.
Article
CAS
PubMed
Google Scholar
Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res, 2010,70:2235–2244.
Article
CAS
PubMed
Google Scholar